Read Also: Streaming Stock’s Revenues Quadrupled ... PepGen says the company plans to advance PGN-EDODM1 into multiple-dose studies and expects additional results from the 15 mg/kg cohort ...

spurring a significant stock drop. The Boston-based biotech said on Tuesday morning it would voluntarily pause a Phase 2 study of its drug, PGN-EDO51, in patients with Duchenne muscular dystrophy ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PepGen Inc.

Upstream depends on being able to display ads on our services in order to finance our journalism.

The Supreme Court has always been referred to as the last bulwark of democracy. People’s continued faith in the judiciary demonstrates Filipinos’ high regard for the integrity of the nation’s highest ...

Our investment, which came to $16.6 billion ... We also started operations at PGN, the natural gas production in the state of Rio de Janeiro as well as the sulfur unit in the Pernambuco unit ...

Lazaro-Javier cited the PGN Island Bridges project ... The COA report stated: “The accounting errors in the recognition and measurement of Investment in Bonds and Accrued Interest Receivable resulted ...

making it the fastest-growing biotech stock by retail engagement in this period. The rally follows PepGen's release of early clinical data from its FREEDOM-DM1 Phase 1 trial, evaluating PGN-EDODM1 ...

Three weeks before, the company earned fast track designation for PGN-EDODM1. Elsewhere in the DMD research field, Solid Biosciences stock recently soared on a positive data readout from a Phase I/II ...

Mainstream media discourse on Donald Trump's new trade wars and reporting on tariffs has not addressed those already living ...